MO968ROUTINE BIOMARKERS FOR THE SEVERITY OF COVID-19 PNEUMONIA MAY PRESENT DIFFERENTLY IN KIDNEY TRANSPLANT RECIPIENTS. (29th May 2021)

• Record Type: Journal Article
• Authors: Burgos García, Elena; Molina Gomez, Maria; Cacho, Judit; Juega Mariã'o, Francisco Javier; Cañas Sole, Laura; Taco, Omar; Pérez-Mir, Mónica; Urrutia, Marina; Graterol, Fredzzia; Lauzurica, Ricardo
• Is Part Of: Nephrology dialysis transplantation. Volume 36(2021)Supplement 1
• Publication Date: 2021-05-29
• Subjects: Nephrology -- Periodicals; Hemodialysis -- Periodicals; Kidneys -- Transplantation -- Periodicals; Hemodialysis; Kidneys -- Transplantation; Nephrology; Periodicals; 616.61
• DOI: 10.1093/ndt/gfab110.0047
• Languages: English
• ISSNs: 0931-0509

Abstract

Abstract: Background and Aims: The treatment of coronavirus disease (COVID-19) is based on the patient's clinical status and levels of inflammatory biomarkers. The comparative activity of these biomarkers in KT patients with COVID-19 pneumonia from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and non-SARS-CoV-2 aetiologies is unknown. The aim of this study was to compare the clinical presentation and inflammatory parameters at admission of KT patients with COVID-19 pneumonia and those with non-COVID-19 pneumonia over the same period. Method: Biomarkers were measured and compared between KT patients with COVID-19 pneumonia (n=42) and non-COVID-19 pneumonia (n=18) from March to November 2020. Results: Both groups showed comparable demographics. The COVID-19 KT patients had fewer neutrophils (4, 650 [2, 925-9, 498] vs. 9, 100 [7, 170-11, 150], p=0.01) than the non-COVID group, although there was no significant difference in the lymphocyte count. Non-COVID-19 pneumonia was associated with a higher d-dimer (962 [427-1, 448] vs. 1, 704 [868-2, 481], p=0.09) and IL-6 (37 [23-10] vs 254 [53-602], p=0.006) levels. The ferritin level was higher in the COVID-19 group (908 [496-1, 377] vs. 340 [264-785], p=0.008). Conclusion: COVID-19 pneumonia in KT recipients shows a different presentation of inflammatory biomarkers than other non-COVID pneumonias. It could be usefully to identify KT patients with COVID-19.More detailed studies are necessary to understand the presentation of biomarkers in KT with COVID-19.